| 6.61 -0.2 (-2.94%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.28  |
1-year : | 11.97 |
| Resists | First : | 8.8 |
Second : | 10.25 |
| Pivot price | 7.6 |
|||
| Supports | First : | 6.47 |
Second : | 5.38 |
| MAs | MA(5) : | 6.96 |
MA(20) : | 7.96 |
| MA(100) : | 15.29 |
MA(250) : | 14.97  |
|
| MACD | MACD : | -1.2 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 5.8 |
D(3) : | 6.4 |
| RSI | RSI(14): 25.2 |
|||
| 52-week | High : | 25.95 | Low : | 5.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BIOA ] has closed above bottom band by 8.3%. Bollinger Bands are 62.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.93 - 6.98 | 6.98 - 7.02 |
| Low: | 6.35 - 6.41 | 6.41 - 6.46 |
| Close: | 6.52 - 6.61 | 6.61 - 6.67 |
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Fri, 25 Sep 2026
BioAge Labs to Present at Upcoming Investor Conferences - GlobeNewswire
Mon, 21 Sep 2026
BioAge Labs (Nasdaq:BIOA) - Stock Analysis - Simply Wall Street
Tue, 08 Sep 2026
A daily pill for diabetic eye disease enters a Phase 2 trial - Stock Titan
Mon, 10 Aug 2026
We're Not Very Worried About BioAge Labs' (NASDAQ:BIOA) Cash Burn Rate - Moomoo
Wed, 05 Aug 2026
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire
Wed, 05 Aug 2026
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 3.919e+007 (%) |
| Held by Institutions | 2.3 (%) |
| Shares Short | 2,450 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0602e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 196.7 % |
| Return on Equity (ttm) | -18.5 % |
| Qtrly Rev. Growth | 1.036e+007 % |
| Gross Profit (p.s.) | -1.65 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -2.29 |
| Qtrly Earnings Growth | -2.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -88 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 28.47 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.22e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|